Skip To Main Content

Artikelen

Sort by

Filters

Resetten
  • Therapeutische gebieden
How to diagnose Fabry

How to diagnose Fabry

Think Fabry, think timely testing first.

Monitoring disease progression

Monitoring disease progression

Think Fabry, think regular profile-based assessments.

Cardiac involvement in Fabry disease

Cardiac involvement in Fabry disease

Cardiovascular disease is the leading cause of death in Fabry disease patients.1 Undiagnosed and untreated Fabry disease leads to progressive, irreversible, life-threatening heart injury.2,3

Renal involvement in Fabry disease

Renal involvement in Fabry disease

Think Fabry, think renal involvement that may present early in life and could go undetected.

Family screening

Family screening

Think Fabry, think screening at-risk family members.1

When to treat

When to treat

Think Fabry, think early treatment to help slow or prevent life-threatening disease progression.1,2

Pooled analysis: Interventional and observational studies

Pooled analysis: Interventional and observational studies

A post-hoc pooled analysis to evaluate efficacy and safety of insulin glargine 300 U/mL in insulin-naïve people with type 2 diabetes with/ without prior use of glucagon-like peptide-1 receptor agonist therapy.1

Efluelda<sup>®</sup> - Seizoensgebonden hoge dosis griepvaccin

Efluelda® - Seizoensgebonden hoge dosis griepvaccin

Efluelda® wordt preferentieel aanbevolen door de Hoge GezondheidsRaad (HGR).

Specifieke aanbevelingen voor versterkte vaccins bij personen ≥ 65 jaar:
Voor alle personen van 65 jaar en ouder wordt bij voorkeur een versterkt griepvaccin aanbevolen (met adjuvans of hooggedoseerd) boven standaardgedoseerde vaccins*

Overview of cGvHD

Overview of cGvHD

Actors

Actors

Immunology mechanism

Immunology mechanism

Effect of cGVHD

Effect of cGVHD